Back to Menu
1. Clinical assessment
Obtain a detailed history of mass growth and perform a physical examination to assess size, consistency, mobility, and neurologic function.
2. Ultrasonography
Used for initial screening to distinguish cystic versus solid lesions and assess vascularity; it can guide needle biopsy and support longitudinal monitoring of tumor changes.
3. MRI examination
The preferred modality, providing clear delineation of the tumor and its relationship to neurovascular structures, thereby informing surgical planning.
4. CT examination
Useful for detecting calcification, osseous involvement, and pulmonary metastases, and for evaluating tumor vascularity and its relationship to adjacent vessels.
5. Pathological biopsy
The gold standard. Core-needle or open biopsy provides tissue for definitive diagnosis and histologic grading.
6. Imaging-based staging
Chest CT and other studies are used to evaluate distant metastasis; PET-CT assesses whole-body metabolic activity and can aid in treatment-response evaluation.
7. Differential diagnosis
Differentiation from inflammatory lesions, hematoma, and other mimics requires integration of imaging features, growth kinetics, and pathology.
8. Molecular diagnostics
Detection of specific genetic alterations (e.g., SYT–SSX fusion) supports subtype classification and may guide targeted therapy selection.
9. Self-check for soft tissue tumors
Be alert to a painless, persistently enlarging hard mass and nocturnal pain, and seek medical evaluation promptly.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that soft tissue tumors carry a risk of malignant transformation, and malignant sarcomas have high rates of recurrence and metastasis, posing a substantial threat to survival and quality of life. Early diagnosis can halt progression, prevent metastasis, and create an opportunity for curative surgery. Early diagnostic work-up and multidisciplinary collaboration are imperative, with individualized treatment strategies guided by molecular classification to avoid delays in care.
1. Clinical assessment
Obtain a detailed history of mass growth and perform a physical examination to assess size, consistency, mobility, and neurologic function.
2. Ultrasonography
Used for initial screening to distinguish cystic versus solid lesions and assess vascularity; it can guide needle biopsy and support longitudinal monitoring of tumor changes.
3. MRI examination
The preferred modality, providing clear delineation of the tumor and its relationship to neurovascular structures, thereby informing surgical planning.
4. CT examination
Useful for detecting calcification, osseous involvement, and pulmonary metastases, and for evaluating tumor vascularity and its relationship to adjacent vessels.
5. Pathological biopsy
The gold standard. Core-needle or open biopsy provides tissue for definitive diagnosis and histologic grading.
6. Imaging-based staging
Chest CT and other studies are used to evaluate distant metastasis; PET-CT assesses whole-body metabolic activity and can aid in treatment-response evaluation.
7. Differential diagnosis
Differentiation from inflammatory lesions, hematoma, and other mimics requires integration of imaging features, growth kinetics, and pathology.
8. Molecular diagnostics
Detection of specific genetic alterations (e.g., SYT–SSX fusion) supports subtype classification and may guide targeted therapy selection.
9. Self-check for soft tissue tumors
Be alert to a painless, persistently enlarging hard mass and nocturnal pain, and seek medical evaluation promptly.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that soft tissue tumors carry a risk of malignant transformation, and malignant sarcomas have high rates of recurrence and metastasis, posing a substantial threat to survival and quality of life. Early diagnosis can halt progression, prevent metastasis, and create an opportunity for curative surgery. Early diagnostic work-up and multidisciplinary collaboration are imperative, with individualized treatment strategies guided by molecular classification to avoid delays in care.